Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

计划入组 25 人 · 首次发布于 2015 年 8 月 3 日

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

计划入组 1 人 · 首次发布于 2016 年 3 月 1 日

Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants

计划入组 1,000 人 · 首次发布于 2020 年 5 月 1 日

STX-721

Exon 53

Exon 45

19 and Pacific, LLC

United States

SpringWorks Therapeutics

United States

TEXAS RETINA ASSOCIATES

United States

Hansoh Pharma's Aumolertinib Plus Chemotherapy Shows Positive Phase III Results in EGFR-Mutated NSCLC

FDA Issues Complete Response Letter for Subcutaneous Amivantamab in EGFR-Mutated NSCLC

Osimertinib and Amivantamab Gain FDA Approval for EGFR-Mutated NSCLC